BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today announced that an independent Data Monitoring Committee (DMC) completed its prespecified review of interim safety data in the Company’s Phase 1b clinical trial of PH-762 for the treatment of advanced melanoma.

Aristea Therapeutics (Aristea), a clinical-stage immunology focused drug development company advancing novel therapies to treat serious inflammatory diseases, today announced that, due to safety findings in the ongoing Phase 2 clinical trials, it has discontinued the RIST4721 development program in order to protect patient safety.

Q BioMed Inc. (OTCQB: QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, asset Uttroside B – is expected to receive a patent in the United States, adding to the already issued patents in Korea, Canada and Japan.

Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced the positive top-line results from the U.S. Phase I clinical trial of GT20029, a Kintor Pharma in-house developed and fully owned proteolysis targeting chimera (PROTAC) compound.

Ra Medical Systems (NYSE American:RMED) today announced the date of March 21, 2023 as the date of its special shareholder meeting.

Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business.

Dipharma Francis S.r.l. announced the completion of the second phase of expansion of its American site, Dipharma Inc., located in Kalamazoo, MI.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced that RADICAVA® Oral Suspension, the oral formulation of RADICAVA® IV (edaravone), is now commercially available in Canada for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows.

ALK announced that Claus Steensen Sølje will take up the position as Executive Vice President, Chief Financial Officer and member of the Board of Management no later than 1 June 2023.